To assess whether these compounds could interfere with p130Cas/ErbB2 association in a cellular context, ErbB2-positive BT474 breast cancer cells were pre-treated for 24 hours with 1 or 2 and subjected to co-immunoprecipitation experiments. The gene discussed is ERBB2; the disease is breast cancer.